Ultragenyx Pharmaceutical Inc. (RARE)
NASDAQ: RARE · Real-Time Price · USD
25.00
-0.80 (-3.10%)
At close: May 15, 2026, 4:00 PM EDT
25.10
+0.10 (0.40%)
After-hours: May 15, 2026, 7:35 PM EDT
Ultragenyx Pharmaceutical Stock Forecast
Stock Price Forecast
The 20 analysts that cover Ultragenyx Pharmaceutical stock have a consensus rating of "Strong Buy" and an average price target of $58.8, which forecasts a 135.20% increase in the stock price over the next year. The lowest target is $25 and the highest is $105.
Price Target: $58.8 (+135.20%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Ultragenyx Pharmaceutical stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 8 | 8 | 7 | 7 | 7 |
| Buy | 11 | 11 | 11 | 10 | 11 | 11 |
| Hold | 1 | 1 | 1 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 19 | 20 | 20 | 19 | 20 | 20 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wedbush | Wedbush | Hold Maintains $27 → $26 | Hold | Maintains | $27 → $26 | +4.00% | May 8, 2026 |
| Guggenheim | Guggenheim | Strong Buy Maintains $52 → $43 | Strong Buy | Maintains | $52 → $43 | +72.00% | May 8, 2026 |
| Wells Fargo | Wells Fargo | Buy Maintains $45 → $47 | Buy | Maintains | $45 → $47 | +88.00% | May 6, 2026 |
| Wedbush | Wedbush | Hold Maintains $27 → $26 | Hold | Maintains | $27 → $26 | +4.00% | May 6, 2026 |
| Barclays | Barclays | Buy Maintains $44 → $43 | Buy | Maintains | $44 → $43 | +72.00% | Apr 29, 2026 |
Financial Forecast
Revenue This Year
761.90M
from 673.00M
Increased by 13.21%
Revenue Next Year
1.01B
from 761.90M
Increased by 33.09%
EPS This Year
-4.45
from -5.83
EPS Next Year
-1.01
from -4.45
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 863.0M | 1.7B | ||||||
| Avg | 761.9M | 1.0B | ||||||
| Low | 597.5M | 809.1M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 28.2% | 125.6% | ||||||
| Avg | 13.2% | 33.1% | ||||||
| Low | -11.2% | 6.2% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -2.30 | 0.57 | ||||||
| Avg | -4.45 | -1.01 | ||||||
| Low | -5.50 | -2.63 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.